1. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study;Phillips;Lancet HIV,2018
2. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013
3. Thorne C, Favarato G, Peters H, et al. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. 9th IAS Conference on HIV Science; Paris, France; July 23–26, 2017. Abstract 4549.
4. Vannappagari V, Albano J, Ragone L, et al. Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR). 9th IAS Conference on HIV Science. Paris, France; July 23–26, 2017. Abstract 68.
5. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health; in press.